Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Clin Mol Hepatol. 2022 Jul;28(3):553-564. doi: 10.3350/cmh.2022.0082. Epub 2022 May 11.
BACKGROUND/AIMS: Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects.
Two hundred ninety-five subjects who received BNT162b2 or CoronaVac vaccines from five vaccination centers were categorized into moderate/severe HS (controlled attenuation parameter ≥268 dB/m on transient elastography) (n=74) or control (n=221) groups. Primary outcomes were seroconversion rates of neutralising antibody by live virus Microneutralization (vMN) assay (titer ≥10) at day21 (BNT162b2) or day28 (CoronaVac) and day56 (both). Secondary outcome was highest-tier titer response (top 25% of vMN titer; cutoff: 160 [BNT162b2] and 20 [CoronaVac]) at day 56.
For BNT162b2 (n=228, 77.3%), there was no statistical differences in seroconversion rates (day21: 71.7% vs. 76.6%; day56: 100% vs. 100%) or vMN geometric mean titer (GMT) (day21: 13.2 vs. 13.3; day56: 91.9 vs. 101.4) among moderate/severe HS and control groups respectively. However, lower proportion of moderate/severe HS patients had highest-tier response (day56: 5.0% vs. 15.5%; P=0.037). For CoronaVac (n=67, 22.7%), there was no statistical differences in seroconversion rates (day21: 7.1% vs. 15.1%; day56: 64.3% vs. 83.0%) or vMN GMT (5.3 vs. 5.8,) at day28. However, moderate/severe HS patients had lower vMN GMT (9.1 vs. 14.8, P=0.021) at day 56 with lower proportion having highest-tier response (21.4% vs. 52.8%, P=0.036).
While there was no difference in seroconversion rate between moderate/severe HS and control groups after two doses of vaccine, a lower proportion of moderate/severe HS patients achieved highest-tier response for either BNT162b2 or CoronaVac.
背景/目的：目前缺乏关于肝脂肪变性（HS）对 COVID-19 疫苗免疫原性影响的研究。我们旨在比较中重度 HS 患者和对照组接受 BNT162b2 和 CoronaVac 疫苗的免疫原性。
295 名在五家接种中心接受 BNT162b2 或 CoronaVac 疫苗的受试者被分为中重度 HS 组（瞬时弹性成像受控衰减参数≥268 dB/m）（n=74）或对照组（n=221）。主要结局为在第 21 天（BNT162b2）或第 28 天（CoronaVac）和第 56 天（两者）的活病毒微量中和（vMN）检测（滴度≥10）的中和抗体血清转化率。次要结局为第 56 天的最高滴度反应（最高 25%的 vMN 滴度；截止值：160[BNT162b2]和 20[CoronaVac]）。
对于 BNT162b2（n=228，77.3%），在血清转化率（第 21 天：71.7% vs. 76.6%；第 56 天：100% vs. 100%）或 vMN 几何平均滴度（GMT）（第 21 天：13.2 vs. 13.3；第 56 天：91.9 vs. 101.4）方面，中重度 HS 组和对照组之间均无统计学差异。然而，中重度 HS 患者中具有最高滴度反应的比例较低（第 56 天：5.0% vs. 15.5%；P=0.037）。对于 CoronaVac（n=67，22.7%），在血清转化率（第 21 天：7.1% vs. 15.1%；第 56 天：64.3% vs. 83.0%）或 vMN GMT（5.3 vs. 5.8）方面，第 28 天均无统计学差异。然而，中重度 HS 患者在第 56 天的 vMN GMT 较低（9.1 vs. 14.8，P=0.021），且具有最高滴度反应的比例较低（21.4% vs. 52.8%，P=0.036）。
尽管在接种两剂疫苗后，中重度 HS 组和对照组的血清转化率无差异，但对于 BNT162b2 或 CoronaVac，中重度 HS 患者中具有最高滴度反应的比例较低。
